Cargando…
Can molecular stratification improve the treatment of inflammatory bowel disease?
Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease of the gastrointestinal (GI) tract. It affects more than 3.5 million people in the western world and places a huge financial burden on healthcare systems. IBD is highly heterogeneous; disease severity and outcomes in IBD...
Autores principales: | Wang, Claire, Baer, Hannah M., Gaya, Daniel R., Nibbs, Robert J.B., Milling, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902263/ https://www.ncbi.nlm.nih.gov/pubmed/31491469 http://dx.doi.org/10.1016/j.phrs.2019.104442 |
Ejemplares similares
-
The mannose receptor (CD206) identifies a population of colonic macrophages in health and inflammatory bowel disease
por: Wright, Pamela B., et al.
Publicado: (2021) -
Dietary Strategies for Maintenance of Clinical Remission in Inflammatory Bowel Diseases: Are We There Yet?
por: Gkikas, Konstantinos, et al.
Publicado: (2020) -
Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease
por: Moustafa, Ahmed, et al.
Publicado: (2018) -
Improving the quality of care for inflammatory bowel disease
por: Ye, Byong Duk, et al.
Publicado: (2019) -
A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study
por: Cummings, Fraser, et al.
Publicado: (2019)